China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk

The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk

BioMed X launches Harvard pilot to connect academia and pharma

Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements

Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy

The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production

Akums and Sharda University ink MoU to bridge industry–academia gap

The primary goal of the collaboration is joint research into trending and next-generation molecules

FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia

The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia

Industry-academia partnership key to advancing R&D agenda, says Dr. Jitendra Singh

Growing patent filings and tier-2 innovators reflect expanding national research base

NHS’s breakthrough leukaemia therapy set to transform lives in UK

Clinical trials found that 77% of patients went into remission after receiving obe-cel